Suppliers / Yichang Sanxia Pharmaceutical

Yichang Sanxia Pharmaceutical

China Updated 9 July 2026

Yichang Sanxia Pharmaceutical is an API and finished-dose manufacturer based in China. It holds one active US drug master file and 2 valid CEPs across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 8 September 2023 as NAI.

1
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 8 September 2023 NAI US FDA
  • 15 July 2016 VAI US FDA
  • 16 June 2011 NAI US FDA
  • 23 July 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Yichang, China Not on file
China, China 3003274512

What they file, and where

Molecule Regulators Docs
Neomycin EDQM, SFDA (Saudi Arabia), US FDA 3
Neomycin Sulfate EDQM 1

Also appears on these molecule pages

Alanine finished dose Arginine finished dose Aspartic Acid finished dose Glutamic Acid finished dose Histidine finished dose Isoleucine finished dose Leucine finished dose Neomycin API Phenylalanine finished dose Proline finished dose Serine finished dose Threonine finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
UZPHARM (UZ) 2 None
US FDA None 1

Questions about Yichang Sanxia Pharmaceutical

Does Yichang Sanxia Pharmaceutical hold a US DMF or a CEP?
Yichang Sanxia Pharmaceutical holds 1 active US drug master file and 2 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Yichang Sanxia Pharmaceutical FDA-registered?
One site operated by Yichang Sanxia Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Yichang Sanxia Pharmaceutical's last inspection go?
The most recent inspection on record closed on 8 September 2023 as NAI (No Action Indicated: nothing objectionable was found). 4 inspections are on file.
Where does Yichang Sanxia Pharmaceutical manufacture?
2 registered sites are on record, in China (Yichang and China). Every site is listed on this page with the register it came from.
What does Yichang Sanxia Pharmaceutical make?
2 molecules are on record against Yichang Sanxia Pharmaceutical, including Neomycin and Neomycin Sulfate. Each links through to that molecule's full manufacturer list.
Which regulators recognise Yichang Sanxia Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Checking Yichang Sanxia Pharmaceutical?

Ask Fred what the record holds on Yichang Sanxia Pharmaceutical, including filings and inspection history.

Chat with Fred, your AI analyst
Opens WhatsApp. Free to start.

Open risk flags

  • The most recent inspection outcome was NAI, on 8 September 2023.

Comparable suppliers

PHARMACIA & UPJOHN shares 1 molecule Sichuan Long March Pharmaceutical shares 1 molecule Huashu Pharmaceutical shares 1 molecule Pharmacia & UpJohn shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates